Abstract: System and method are provided for achieving “inverse kinematics” of 3D graphics depicting an object that consists of multiple parts. The system displays an animation of a 3D graphics object that consists of multiple moving parts. The animation is associated with an animation timeline defined by two end points—a starting time point and an ending time point. The user can manipulate the object back and forth along the animation timeline, between the two end points, by selecting (e.g., clicking on) and moving (dragging) any of the movable parts of the object on a display screen. In short, the user can use any of the movable parts as a scroll/slide button to move the animation forward and backward along the animation timeline, to achieve real-time inverse kinematics movement.

Abstract: System and method are provided for building and rendering a 3D graphics dataset of an object that consists of multiple parts, wherein the 3D graphics dataset includes a 3D geometry dataset and a configuration file, and in the configuration file each of the multiple parts is identified as used (e.g., visible, actionable) or unused (e.g., not visible, not actionable) in each of multiple display features (e.g., in display states, such as in animations, or in display relationships). The method determines which of the multiple parts are unused in each of the multiple display features and identifies those parts, which are unused in all of the display features, as excluded parts, and saves a list of the identified excluded parts in association with the object. In rendering the object on a display, the method does not load data directed to the excluded parts, to thereby speed up the loading/rendering process.

Abstract: System and method are provided for building and rendering a 3D graphics dataset of an object that consists of multiple parts, wherein the 3D graphics dataset includes a 3D geometry dataset and a configuration file, and in the configuration file each of the multiple parts is identified as used (e.g., visible, actionable) or unused (e.g., not visible, not actionable) in each of multiple display features (e.g., in display states, such as in animations, or in display relationships). The method determines which of the multiple parts are unused in each of the multiple display features and identifies those parts, which are unused in all of the display features, as excluded parts, and saves a list of the identified excluded parts in association with the object. In rendering the object on a display, the method does not load data directed to the excluded parts, to thereby speed up the loading/rendering process.

Abstract: System and method are provided for achieving “inverse kinematics” of 3D graphics depicting an object that consists of multiple parts. The system displays an animation of a 3D graphics object that consists of multiple moving parts. The animation is associated with an animation timeline defined by two end points—a starting time point and an ending time point. The user can manipulate the object back and forth along the animation timeline, between the two end points, by selecting (e.g., clicking on) and moving (dragging) any of the movable parts of the object on a display screen. In short, the user can use any of the movable parts as a scroll/slide button to move the animation forward and backward along the animation timeline, to achieve real-time inverse kinematics movement.

Abstract: The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by systemic administration of a colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis.

Abstract: This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamia interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: Novel means and methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes involve selecting probe sets that define reference sequences for sequence signatures and deriving useful data about the nature of the target nucleic acid molecule based on its hybridization to the probes. The methods are useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes.

Abstract: This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample.

Abstract: This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample.

Abstract: Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed “adzymes,” comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer a new specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.

Abstract: Novel means and methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes involve selecting probe sets that define reference sequences for sequence signatures and deriving useful data about the nature of the target nucleic acid molecule based on its hybridization to the probes. The methods are useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample.

Abstract: This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample.

Abstract: An apparatus for delivering medicinal aerosol on-demand during patient inhalation wherein delivery of aerosol from a nebulizer (22) is optimized by synchronizing delivery to the inspiration of a patient (58)is disclosed. A control unit (32) monitors airway pressure and controls the flow of gas so that aerosol delivery is triggered by patient inhalation, in which event delivery continues for a predetermined time period which is adjustable by the user. The apparatus can be used with a mouthpiece (56), a face mask (66) without an integral exhalation valve, or a face mask (68) with an integral exhalation valve. The apparatus significantly increases the efficiency of delivery of medicinal aerosol by sensing a patient's inhalation and exhalation cycles and delivering aerosol only after a certain inhalation pressure is sensed following a certain previous exhalation pressure. These pressures, which are compared against predetermined thresholds, correspond to the actual patient breathing condition.

Abstract: A nebulizer (10) for generating high concentrations of inhalable medicinal aerosols over a wide range of flow rates and mass outputs for medical inhalation therapy applications. A primary orifice (26), secondary orifice (44), inter-orifice gap (54), stagnation baffle (60), and spray gap (66) are scalable within defined parameters to provide any desired flow rate or mass output. The nebulizer is ideally suited for inhalation therapy of infants and children and can provide aerosols with flow rates ranging from less than 1 liter per minute to approximately 3 liters per minute at normal compressed gas pressures. The design parameters can also be scaled within defined limits to produce greater flows for treatment of adults or for use in other applications requiring high volumetric flow rates.

Abstract: A fluid injector for use with a needle-less syringe or needle-less add-on IV line is disclosed. The injector is connected to a main IV line and has a fluid passageway from the syringe or the add-on IV set to the main IV line. The injector comprises an anti-backflow valve member where the member is movable under fluid pressure along between a first position where the fluid cannot flow through the injector and a second position where the fluid can flow through the injector. The member is a sinking type and has a specific gravity greater than 1.0. The injector also comprises a valve located near the syringe end of the injector for receiving the fluid from the syringe or the add-on IV line for injection into the main IV line and for automatically preventing air embolus entering into the IV line. The anti-air embolus valve comprises a piston in a conduit. The piston is movable between a first position and a second position. The piston has a central bore for the passage of the fluid, a capped end and an inlet end.

Abstract: A fluid injector for use with a needle-less syringe or needle-less add-on IV line is disclosed. The injector is connected to a main IV line and has a fluid passageway from the syringe or the add-on IV set to the main IV line. The injector comprises an anti-backflow valve member where the member is movable under fluid pressure alone between a first position where the fluid can flow through the injector and a second position where the fluid cannot flow through the injector. The injector also comprises a valve located near the syringe end of the injector for receiving the fluid from the syringe or the add-on IV line for injection into the main IV line and for preventing air embolus entering into the IV line. The injector permits leaving a single or a group of drug filled syringes on line at all times with a continuously, rapidly flowing IV line and provides instantaneous "on demand" delivery of drugs or fluids from the syringe.

Abstract: A device is disclosed for dispersing a fluid supplied from an external source having a feed supply. An inlet accepts a fluid from the feed supply for passing the fluid through an outer perimeter of the device in a downstream direction and has an axes contained in a plane. An outlet is provided downstream from the inlet for allowing the fluid to exit. A bluff body is positioned between the inlet and the outlet and has an axes contained in a plane perpendicular to the inlet axes plane. At least one passageway internal to the outer perimeter and external and extending downstream from the outlet for passing a second fluid is provided.